| Revenue growth | 21% YoY |
|---|---|
| Margins | EBITDA margin improved to 36.0% (Ind AS) |
| Demand visibility | Strong network expansion momentum |
| Management confidence | Strong footing beginning FY27 |
Growth
Revenue grew 21% YoY to INR 876.5 Mn; EBITDA rose 28% to INR 315.3 Mn; PAT jumped 40% to INR 128.5 Mn.
Outlook
Aggressive expansion with 4 hubs and 7 spokes upcoming in FY27; Genomics vertical expected to become a meaningful pillar.
Risks
Execution risks in new geographies (Jharkhand/Bihar) and potential schedule changes for analyst calls due to exigencies.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 21% (= BEAT)
- Guided EBITDA margin 33% → delivered 36% (= BEAT)
- Guided regional expansion beyond WB → delivered hubs in Berhampur and Dhanbad (= BEAT)
Partly delivered
- Guided 14 centers in FY27 → delivered 4 hubs and 7 spokes in progress (= PARTIAL)
Investor Presentation filed with BSE, NSE: SURAKSHA. Summary written with AI assistance from the document.
Suraksha Diagnostic Ltd: key numbers
- Share price
- ₹343.30
- Market cap
- ₹1,788 Cr
- Revenue (annual)
- ₹310.4 Cr
- Net profit (annual)
- ₹32.19 Cr
- P/E (TTM)
- 50.0×Sector 57.8×
- Promoter holding
- 49.10%+0.00% QoQ
- FII holding
- 13.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suraksha Diagnostic Ltd
All →Suraksha Diagnostic Annual General Meeting
Suraksha Diagnostic Ltd held its 21st AGM on September 22, 2026. Members adopted financial statements, approved a final dividend, and ratified cost auditor remuneration.
Suraksha Diagnostic Earnings Call Transcript: Key Takeaways
Suraksha Diagnostic reported a robust Q1 FY27 with 21% revenue growth and 40% PAT growth, driven by expansion in West Bengal and Jharkhand and a high-growth genomics segment.
- Call
- Guides 15% growth
Suraksha Diagnostic Q1 FY27 Results: Net Profit ₹12.8 Cr, Up 39.1% YoY
Suraksha Diagnostic Ltd reported revenue from operations of ₹87.6 Cr (+20.7% YoY) and net profit of ₹12.8 Cr (+39.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹12.8 Cr · +39.1% YoY
Suraksha Diagnostic Earnings Call: Key Takeaways
Suraksha Diagnostic Limited concluded FY26 with 23.1% revenue growth to INR 3104M. Strategy shifts towards specialized genomics and multi-state expansion into Bihar, Tripura, and Jharkhand.
Suraksha Diagnostic Earnings Call: Key Takeaways
Suraksha Diagnostic reported robust FY26 revenue growth of 23.1% YoY, driven by aggressive regional expansion and a shift toward high-value genomic and specialized radiology testing.
Suraksha Diagnostic Earnings Call: Key Takeaways
Suraksha Diagnostic reported robust FY26 results with 23% revenue growth and 16% EBITDA growth, driven by core diagnostic momentum and expansion in Eastern India.